Law360, New York (July 11, 2006, 12:00 AM EDT) -- Famed trial attorney Mark Lanier doesn’t bestow compliments on pharmaceutical defense firms all that often. Lanier, who yielded first $253 million, and later $13 million, from Merck in the Vioxx trials, could only come up with one firm to compliment when asked about his competition: Dechert.
“In all candor, I have not been too impressed with many others,” Lanier said, singling out Philadelphia-based Dechert partner Hope Freiwald as “top notch.”
Freiwald and partner Diane Sullivan also scored a major win in a Vioxx case, securing a...
Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.